↧
Biosimilars in Latin America
Desanvicente-Celis Z, Caro-Moreno J, Enciso-Zuluaga M, Anaya JM
View ArticleClinical efficacy and safety of biosimilar erythropoietin SB309
Bagalagel A, Mohammed A, MacDonald K, Abraham I
View ArticleClinical efficacy and safety of Tevagrastim
Bagalagel A, Mohammed A, MacDonald K, Abraham I
View ArticleClinical efficacy and safety of biosimilar erythropoietin XM01
Mohammed A, Bagalagel A, MacDonald K, Abraham I
View ArticleClinical efficacy and safety of Zarzio
Tharmarajah S, Mohammed A, Bagalagel A, MacDonald K, Abraham I
View ArticleCharacterization of biosimilar adalimumab
Bandyopadhyay S, Mahajan M, Mehta T, Singh AK, Parikh A, Gupta AK, Kalita P, Patel M, Mendiratta SK
View ArticleClinical trials in the development of biosimilars
Huneycutt BJ, Gillespie E, Woollett GR
View ArticleLow immunogenicity but reduced bioavailability of an IFN beta-1a biosimilar
Cuevas C, Deisenhammer F, You X, Scolnik M, Buffels R, Sperling B, Flores-Ramírez F, Macías-Islas M, Sauri-Suárez S
View Article